Analyzing Clinical Trial Experiences of Prostate Cancer Patients

NCT05411354 | Not Yet Recruiting

• 1 other identifier: 585375c1448bfa3494298bdd794080
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the participation or completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Prostate Cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might shed insights for the sake of future Prostate Cancer patients.

Conditions

Prostate Cancer

Keywords

Prostate Cancer; Prostate; Prostate Clinical Trials

Outcome Measures

Primary Outcomes (2)

• Rate of patients who decide to enroll in a Prostate Cancer Clinical Trial

  3 months

• Number of patients who remain in Prostate Cancer clinical trial until completion of clinical trial

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Prostate Cancer patients who are actively considering enrolling in an interventional clinical trial to treat their Prostate Cancer, but have yet to complete randomization and enrollment.

You may qualify if:

• Patient has been diagnosed with Prostate Cancer as identified by imaging
• Patient has self-identified as planning to enroll in an interventional clinical trial for Prostate Cancer
• Patient is at least 18 years of age

You may not qualify if:

• Patient does not understand, sign, and return consent form
• Inability to perform regular electronic reporting
• Patient has a ECOG score of 4

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (2)

• McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, Rencsok EM, Simmons S, Yates C, Vinson J, Kantoff PW, George DJ, Mucci LA. Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. JCO Glob Oncol. 2021 Apr;7:495-505. doi: 10.1200/GO.20.00571.

  PMID: 33835826 BACKGROUND

• Rencsok EM, Bazzi LA, McKay RR, Huang FW, Friedant A, Vinson J, Peisch S, Zarif JC, Simmons S, Hawthorne K, Villanti P, Kantoff PW, Heath E, George DJ, Mucci LA. Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1374-1380. doi: 10.1158/1055-9965.EPI-19-1616. Epub 2020 Jun 5.

  PMID: 32503813 BACKGROUND

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Michael B Gill

  Power Life Science Inc

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-287-9919; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 5, 2022
• First Posted: June 9, 2022
• Study Start: September 1, 2024
• Primary Completion: September 1, 2025
• Study Completion (Estimated): September 1, 2026
• Last Updated: January 2, 2024

Record last verified: 2023-12

Locations

US (1)